Skip to main content
Clinical Trials/IRCT2014051117644N1
IRCT2014051117644N1
Completed
Phase 3

Comparison of clinical, radiologic and pathologic response rates of neoadjuvant chemotherapy regimen containing doxorubicin and cyclophosphamide with paclitaxel and gemcitabine in locally advanced breast cancer

Vice chancellor for research, Shiraz University of Medical Sciences0 sites70 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Breast cancer.
Sponsor
Vice chancellor for research, Shiraz University of Medical Sciences
Enrollment
70
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice chancellor for research, Shiraz University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • A) positive pathology of breast cancer; Karnofsky performance status at least: 70; locally advanced breast cancer; age\< 65 Years old; normal cardiac and liver and bone marrow function; normal and acceptable cardiac evaluation in high risk patients or past medical history of cardiac problem; filling the informed consent by patient.
  • B) Exclusion criteria: receiving previous chemotherapy for breast cancer; clinical or pathological positive evidence of metastasis; underling disease which can’t receive chemotherapy; known contraindication for chemotherapy agent (taxan reaction); sever cardiac problem history such as heart failure, chest pain which needs medication, sever cardiac valve disease, myocardial infarction, uncontrolled blood pressure (systolic pressure above 180 mm/Hg and diastolic pressure above 100 mm/Hg); refusing treatment by patient.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials